Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriasis Vulgaris
Interventions: Calcipotriol plus hydrocortisone (LEO 80190); Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions: Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: CD 2027, Calcitriol Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Fridley, Minnesota • Nashville, Tennessee

Conditions: Psoriasis
Interventions: BMS-986165, Placebo for BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Irvine, California • San Diego, California • Ocala, Florida + 13 more

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: No intervention; Other
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Ann Arbor, Michigan + 6 more

Conditions: Psoriasis, Pregnancy
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Birmingham, Alabama • Encinitas, California • Encino, California + 41 more

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Psoriasis
Interventions: Bicillin L-A; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, RLD; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Plaque Psoriasis
Interventions: tapinarof cream, 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: Rogers, Arkansas • Fountain Valley, California • Rancho Santa Margarita, California + 8 more

Conditions: Psoriasis Vulgaris
Interventions: CTLA4Ig / Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 10
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Acne, Actinic Keratosis, Dysplastic Nevi, Eczema, Psoriasis, Skin Cancer, Rosacea, Leg Ulcers, Foot Ulcers, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions: painACTION: Arthritis; Behavioral
Lead sponsor: Inflexxion, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Inflammatory Bowel Diseases
Interventions: Serial Biopsy; Procedure
Lead sponsor: Terrence A Barrett; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: VTAMA® (tapinarof) Cream 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Los Angeles, California • Boca Raton, Florida + 4 more

Conditions: Psoriasis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 12 more

Conditions: Plaque Psoriasis, Vitamin D3
Interventions: Triamcinolone, Vitamin D3, Placebo; Drug · Dietary Supplement
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Psoriasis
Interventions: DFD06; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Madera, California • Santa Ana, California • Hialeah, Florida + 5 more

Search by objective public record fields.

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

PatientSpot Formerly Known as ArthritisPower

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Potential Research Study Participant Registry

Web-based Support to Manage Arthritis Pain

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06